High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies
Not available.
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-01-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11898 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|